Harper, Hooper Exit As Amgen Revenues Rise
Executive Summary
Amgen revealed better-than-expected second quarter earnings July 26 and said its R&D and commercial heads Sean Harper and Anthony Hooper are retiring. Harper, who's getting involved with start-ups, is being replaced from within by David Reese; Bristol's Murdo Gordon will take over for Hooper.
You may also be interested in...
Amgen Expands R&D C-Suite As Reese Focuses On Technology, Bradner Leads R&D
Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.
Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing
Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.
Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing
Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.